A king in the CASTLE? Optimum initial HIV protease inhibitor.
Torti
Carlo
C
Institute of Infectious and Tropical Diseases, University of Brescia, I-25123 Brescia, Italy.
Frank
Ian
I
D000069446:Atazanavir Sulfate; D004338:Drug Combinations; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D061466:Lopinavir; D009842:Oligopeptides / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011725:Pyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D019438:Ritonavir / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013607:Tablets; D019562:Viral Load
D004338:Drug Combinations; D017320:HIV Protease Inhibitors; D009842:Oligopeptides; D011725:Pyridines; D011744:Pyrimidinones; D013607:Tablets; D061466:Lopinavir; D000069446:Atazanavir Sulfate; D019438:Ritonavir